MIRA PHARMACEUTICALS, INC. — Form 8-K
Filed September 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 8/100
What the filing says
MIRA Pharmaceuticals filed an 8-K on September 16, 2026, reporting submission of matters to a stockholder vote (Item 5.07) with period of report September 11, 2026. The filing contains no disclosed transaction details, financial statements, or quantified business impacts. Only XBRL formatting files are attached; substantive terms of any voted matter are not provided in this document extract.
Why this rating
Routine 8-K disclosure of shareholder vote; no financial or operational specifics disclosed. Significance minimal absent quantified transaction terms or outcomes.
Extracted items
- 5.07 shareholder vote
- 9.01 exhibits
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.